Single-Arm Study of Zeprumetostat with Glofitamab in Relapsed/Refractory DLBCL
A single-arm clinical study is investigating the combination of Zeprumetostat, Glofitamab, and GemOx in patients with relapsed/refractory DLBCL.
Asset / Drug
Drug and asset intelligence for Zeprumetostat with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.